Study led by Dr. Martin Kolb releases findings on combination therapy for IPF
Dr. Martin Kolb, research director of the Firestone Institute for Respiratory Health
Dr. Martin Kolb‘s latest publication is Firestone’s fifth paper to be published in the New England Journal of Medicine in recent months, a remarkable achievement.
New research from the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton has reported the results of a combined regimen of nintedanib plus sildenafil. While this combination was not more effective than nintedanib alone in improving symptoms, when used in the treatment of idiopathic pulmonary fibrosis (IPF), it showed remarkable effects on lung function.